Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Nocodazole

Copy Product Info
😃Good
Catalog No. T2802Cas No. 31430-18-9
Alias R17934, Oncodazole

Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis.

Nocodazole

Nocodazole

Copy Product Info
😃Good
Purity: 99.91%
Catalog No. T2802Alias R17934, OncodazoleCas No. 31430-18-9
Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
5 mg$31In StockIn Stock
10 mg$50In StockIn Stock
25 mg$100In StockIn Stock
50 mg$177In StockIn Stock
100 mg$297In StockIn Stock
200 mg$443In StockIn Stock
500 mg$718-In Stock
1 mL x 10 mM (in DMSO)$34In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.91%
Color:White to Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis.
Targets&IC50
B-Raf:1.8 μM (Kd), MEK2:1.6 μM (Kd), PI3Kγ:1.5 μM (Kd), Abl (E255K):0.53 μM, MET:1.7 μM (Kd), MEK1:1.7 μM (Kd), Abl (T315I):0.64 μM, c-Kit:1.6 μM (Kd), Abl:0.21 μM, B-Raf (V600E):1.1 μM (Kd)
In vitro
METHODS: Erythrocytes were treated with Nocodazole (15-60 µg/mL) for 48 h. Phosphatidylserine was detected using Annexin-V-FITC.
RESULTS: Nocodazole treatment increased the percentage of phosphatidylserine exposed to erythrocytes, reaching statistical significance at 30 µg/mL. [1]
METHODS: hESCs cells were treated with Nocodazole (100 ng/mL) for 16 h and cell cycle profiles were analyzed using Flow Cytometry.
RESULTS: Nocodazole treatment synchronized the cell cycle (>90% of cells in G2/M), while cells remained synchronized after release and moved evenly through the cell cycle for 24 h. At 2 h after removal of Nocodazole, the cells entered the G1 phase, with 70% of the cells in the G1 phase after 4 h, and 80% in the S phase after 12 h. The cells were treated with Nocodazole (100 ng/mL) for 16 h, and the cell cycle was analyzed by Flow Cytometry. [2]
In vivo
METHODS: To detect anti-tumor activity in vivo, Nocodazole (12 mg/kg three times a week) and dexamethasone (2 mg/kg twice a week) were injected intraperitoneally for fifteen days into immunodeficient mice bearing myeloma H929.
RESULTS: Nocodazole in combination with dexamethasone significantly inhibited myeloma tumor growth and prolonged survival. [3]
METHODS: To study the effects on intestinal mucositis, Nocodazole (5 mg/kg) and ketoconazole (50 mg/kg) were administered intraperitoneally three times a week for six weeks to nude mice harboring the human colorectal cancer tumor COLO 205.
RESULTS: The antitumor effect of Nocodazole was significantly enhanced after six weeks of ketoconazole treatment. [4]
Cell Research
Nocodazole is dissolved in a final concentration of 0.05% DMSO. Proteins are loaded at 50 μg/lane and separated by 12% (w:v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted, and probed with antibodies for cyclin E, p53, p21/CIP1, p27/KIP1, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), cyclin A, cyclin D1, cyclin D3, cyclin B, CDK2, CDK4, and cytochrome C. Immunoreactive bands are visualized by incubating with the colorigenic substrates nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate. The expression of GAPDH is used as the control for equal protein loading.
SynonymsR17934, Oncodazole
Chemical Properties
Molecular Weight301.32
FormulaC14H11N3O3S
Cas No.31430-18-9
SmilesCOC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1
Relative Density.1.49 g/cm3
Storage & Solubility Information
Storagestore at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 20 mg/mL (66.37 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.64 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.3187 mL16.5937 mL33.1873 mL165.9365 mL
5 mM0.6637 mL3.3187 mL6.6375 mL33.1873 mL
10 mM0.3319 mL1.6594 mL3.3187 mL16.5937 mL
20 mM0.1659 mL0.8297 mL1.6594 mL8.2968 mL
50 mM0.0664 mL0.3319 mL0.6637 mL3.3187 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Nocodazole | purchase Nocodazole | Nocodazole cost | order Nocodazole | Nocodazole chemical structure | Nocodazole in vivo | Nocodazole in vitro | Nocodazole formula | Nocodazole molecular weight